Anteris Technologies Global Corp. (NASDAQ:AVR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.00.

AVR has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price target on shares of Anteris Technologies Global in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th.

Insider Activity at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $8.20, for a total value of $4,580,790.60. Following the sale, the insider directly owned 6,633,314 shares in the company, valued at $54,393,174.80. This trade represents a 7.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 3,008,459 shares of company stock worth $25,243,576 in the last three months. 4.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Anteris Technologies Global

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Anteris Technologies Global in the second quarter worth about $56,846,000. Nantahala Capital Management LLC purchased a new position in Anteris Technologies Global during the second quarter valued at approximately $33,325,850. ADAR1 Capital Management LLC acquired a new position in shares of Anteris Technologies Global in the second quarter worth $30,979,000. Perceptive Advisors LLC increased its position in Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after purchasing an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC bought a new position in Anteris Technologies Global during the first quarter valued at about $3,663,000.

Anteris Technologies Global Stock Down 0.1%

Shares of NASDAQ:AVR opened at $8.15 on Thursday. The firm’s 50 day moving average price is $8.62 and its 200 day moving average price is $7.90. The stock has a market cap of $794.28 million, a price-to-earnings ratio of -4.18 and a beta of 1.80. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.The company had revenue of $1.01 million for the quarter, compared to analyst estimates of $1.50 million. During the same period in the previous year, the business posted ($0.58) EPS. On average, equities analysts anticipate that Anteris Technologies Global will post -1.21 EPS for the current year.

About Anteris Technologies Global

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.